SOUTH SAN FRANCISCO, Calif. , April 5, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 28, 2024 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of the Company's common stock to two newly... Read More

SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event. Stifel Virtual Targeted Oncology Forum Tuesday, April 16 th , 2024 at 12:00 PM ET Fireside chat with Yujiro S. Hata , Chief Executive Officer, hosted... Read More

­Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer Potential first-in-class PARG inhibitor, in combination with anti-PD-1 therapy, targets two complementary mechanisms of anti-tumor immune response in endometrial cancer IDEAYA will sponsor the clinical trial and Merck will provide... Read More

SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events. Leerink Partners Global Biopharma Conference Monday, March 11 th , 2024 at 12:40 PM ET • Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Andrew... Read More

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study Targeting FDA regulatory guidance on darovasertib in neoadjuvant UM indication in 2024 Ongoing enrollment of IDE397 and AMG 193 Phase 1 combo in MTAP solid tumors and targeting development of joint Amgen / IDEAYA publication strategy in... Read More

SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events. Oppenheimer 34 th Annual Healthcare Life Sciences Conference Wednesday, February 14 th , 2024 at 1:20 PM ET Fireside chat with Yujiro S. Hata, Chief... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 25, 2024 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 123,000 shares of the Company's common stock to three... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2024 /PRNewswire/ -- I DEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42 nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates. 42 nd Annual J.P. Morgan Healthcare Conference Tuesday, January 9 th , 2024 at 8:15 AM PT... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 29, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on December 28, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,500 shares of the Company's common stock to a... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 8, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 30, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company's common stock to a newly... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event. Barclays Lunchtime Fireside Chat Series Tuesday, December 5 th , 2023 at 12:00 PM ET Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by... Read More

Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2 directed ADC, in MTAP-deletion bladder cancer Potential first-in-class MAT2A-Trop2 ADC clinical combination targets two distinct, mechanistically complementary, nodes of MTAP-deletion bladder cancer pathway MTAP-deletion prevalence... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 4, 2023 at 8:00 am to 9:30 am ET . The presentations by IDEAYA management and key opinion leaders will... Read More

Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023 , supplemented by $134.7 million estimated net proceeds from subsequent follow-on financing and $10.0 million receivable from GSK milestones Multiple patients dosed and international site activation and enrollment ongoing in Phase 2/3 potential registrational trial evaluating darovasertib and crizotinib... Read More

SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023 . Jefferies London Healthcare Conference Tuesday, November 14 th , 2023 at 8:00 AM GMT |... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,797,872 shares of its common stock at a public offering price of $23.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 319,150 shares of common stock at a public offering price of $23.4999 per pre-funded warrant,... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 26, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 48,000 shares of the Company's common stock to a newly... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 5,000,000 shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $23.50 per share,... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $125.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to... Read More

60% confirmed ORR% by RECIST 1.1 in HLA-A2(+) in 1L MUM, and 42% confirmed ORR% by RECIST 1.1 in HLA-A2(-) in 1L MUM Median PFS of 7.1 months in 1L MUM and 11 months in hepatic-only MUM On further follow-up, ~30% of any-line MUM treated >1 year and multiple PRs on treatment >2 years, with potential for further enhancement with ~20% of patients ongoing treatment Historical ORR% and median PFS by other therapies in MUM have... Read More

Proffered paper oral presentation at ESMO 2023 scheduled for Monday, October 23, 2023 , at 8:50 am CEST will be presented by Dr. Meredith McKean , Sara Cannon Research Institute Darovasertib and Crizotinib combination observed manageable safety profile and clinical efficacy that appears superior to current standard of care in MUM Clinical data update, will include confirmed ORR by RECIST 1.1 by HLA-A2 status, median... Read More

Initiated Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma based on preliminary clinical efficacy observed Approximately 5% of cutaneous melanoma patients harbor a GNAQ/11 mutation, with an estimated annual incidence of ~5,000 patients in the US and ~8,000 patients in the EU28 and total prevalence of ~70,000 patients in the US and ~110,000 patients in the EU28 GNAQ/11 is... Read More

Selected a Werner Helicase Inhibitor Development Candidate in collaboration with GSK Observed monotherapy complete responses preclinically in multiple in vivo xenograft MSI-High models and pharmacological sensitivity in therapy-refractory CRC organoid models Earned $3 million milestone from GSK in connection with IND-enabling studies with potential for up to an additional $17 million aggregate milestones through early Phase... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 28, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a... Read More

Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with HR+, Her2-, BRCA1/2 mutant advanced or metastatic breast cancer patients who have been pretreated with hormonal, CDK4/6 inhibitor and PARP inhibitor therapies Represents a second indication in the IDE161 development program to receive Fast Track designation, complementing the designation for BRCA1/2 mutant ovarian cancer patients... Read More

Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with BRCA1/2 mutant advanced or metastatic ovarian cancer who are platinum resistant and have received prior antiangiogenic and PARP inhibitor therapies Enables IDE161 development program to access expedited regulatory review processes, including potential eligibility for accelerated approval / priority review Ongoing Phase 1 expansion,... Read More

Initiated IDE161 Phase 1 expansion based on preliminary tumor shrinkage observed in multiple HRD solid tumor patients, including an endometrial cancer subject with a first imaging assessment of a partial response and an 87% reduction of the CA-125 tumor marker Phase 1 expansion focus in ER+, Her2(-), HRD+ breast cancer representing ~10% to ~14% of breast cancer as well as HRD+ ovarian cancer and other HRD-associated solid... Read More

SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events. Citi 18 th Annual BioPharma Conference Wednesday, September 6 th , 2023 at 1:00 PM ET Targeted Oncology Panel participation by Paul Stone , Chief... Read More

GSK101 (IDE705) is being developed as a potential first-in-class Pol Theta Helicase Inhibitor in combination with niraparib in GSK-sponsored Phase 1/2 clinical trial GSK101 and niraparib combination development will focus on advanced solid tumors with HR mutations or HRD, pursuant to the clinical protocol IDEAYA to receive a $7 million milestone payment upon IND acceptance, and potential future aggregate milestones of up to... Read More

Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) Preliminary clinical activity observed in primary UM, including tumor shrinkage in 9 of 9 patients following neoadjuvant therapy with darovasertib as monotherapy or in combination with crizotinib, two of whom were spared enucleation and preserved vision... Read More

Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 Initiated Phase 2/3 registrational trial for darovasertib and crizotinib combination in first-line HLA-A2 negative metastatic UM, and also initiated a separate Phase 2 clinical trial to evaluate single-agent darovasertib as neoadjuvant and adjuvant therapy for primary UM... Read More

First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase 1/2 clinical trial ­Global clinical trial will evaluate IDE397 and AMG 193 combination as potential first-in-class synthetic lethality combination in MTAP-deletion patients with planned expansion in NSCLC ­Earlier reported unconfirmed partial response for IDE397... Read More

SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event. BTIG Virtual Biotechnology Conference 2023 Tuesday, August 8 th , 2023 at 3:00 PM ET Fireside chat with Yujiro S. Hata , Chief Executive Officer, hosted... Read More

SOUTH SAN FRANCISCO, Calif. , July 28, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 27, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company's common stock to two newly... Read More

SOUTH SAN FRANCISCO, Calif. , June 30, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 29, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 162,400 shares of the Company's common stock to five... Read More

Eye preservation reported for the first UM patient treated with darovasertib monotherapy under the amended IST protocol enabling neoadjuvant treatment up to 6 months Patient experience shared in an exclusive news report by medical reporter Gabriella Rogers of Television 9 News Channel station in Sydney, Australia on June 21, 2023 Multiple additional UM patients enrolled in enucleation cohort of Phase 1 IST in Australia , led... Read More

Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancers Observed partial response by RECIST 1.1 (~40% tumor reduction) at first post-baseline scan in a pre-treated patient having a high priority MTAP-deletion solid tumor type Clinical strategy focused on IDE397 combinations, including with AMG 193, the Amgen MTA-cooperative... Read More

SOUTH SAN FRANCISCO, Calif. , May 30, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events. Barclays Lunchtime Biotech Fireside Chat Series Thursday, June 1 st , 2023 at 12:00 PM ET Fireside chat with Yujiro S. Hata , Chief Executive Officer,... Read More

SOUTH SAN FRANCISCO, Calif. , May 26, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 25, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a newly... Read More

IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid tumors Potential first-in-class synthetic lethality combination targets mechanistically complementary nodes of the MTAP methylation pathway – MAT2A and PRMT5 Compelling preclinical anti-tumor efficacy presented at AACR 2023 with durable CRs for IDE397 / AMG 193 combination, each at doses below... Read More

Amended clinical trial collaboration and supply agreements with Pfizer to support evaluation of IDEAYA's planned Phase 2/3 registrational clinical trial to evaluate Daro + Crizo in 1L MUM Initiating Phase 2/3 registrational trial in Q2 2023 for darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential AA SOUTH SAN FRANCISCO, Calif. , May 16, 2023 /PRNewswire/... Read More

Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated net proceeds from closing of underwritten public offering on April 27, 2023 , anticipated to fund operations into 2027 Initiating Phase 2/3 registrational trial in Q2 2023 of darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as... Read More

SOUTH SAN FRANCISCO, Calif. , May 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event(s). RBC Capital Markets Global Healthcare Conference Tuesday, May 16 th , 2023 at 11:00 AM ET Fireside chat with Yujiro S. Hata , Chief Executive Officer,... Read More

SOUTH SAN FRANCISCO, Calif. , April 28, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 27, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a newly... Read More

SOUTH SAN FRANCISCO, Calif. , April 27, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 8,858,121 shares of its common stock at a public offering price of $18.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 2,020,270 shares of common stock at a public offering price of $18.4999 per pre-funded... Read More

SOUTH SAN FRANCISCO, Calif. , April 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,439,201 shares of common stock and pre-funded warrants to purchase 2,020,270 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $18.50 per... Read More

SOUTH SAN FRANCISCO, Calif. , April 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $150 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $22.5 million of shares of its common stock. The offering is subject to market and other conditions, and... Read More

Confirmed overall response rate (ORR) of 45%, disease control rate (DCR) of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patients Based on FDA meeting, initiating Phase 2/3 registrational trial in Q2 2023 in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approval Confirmed overall response rate (ORR) of 30%, disease control rate (DCR) of 87% and median PFS of... Read More

Evaluating IDE161 in patients having solid tumors with HRD, with expansion focus in ER+ / Her2- breast cancer with HRD, representing approximately 10% to 14% of breast cancer Dose escalation in patients having HRD solid tumors, with initial dose at one-half of the projected human efficacious dose, based on preclinical efficacy and tolerability studies IDE161 is a potent, selective, small-molecule inhibitor of PARG – a... Read More

SOUTH SAN FRANCISCO, Calif. , April 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event(s). Cantor's The Future of Oncology Virtual Symposium Tuesday, April 4 th , 2023 at 2:15 PM ET Fireside chat with Yujiro Hata , Chief Executive Officer,... Read More

SOUTH SAN FRANCISCO, Calif. , March 31, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 30, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 79,700 shares of the Company's common stock to two... Read More

SOUTH SAN FRANCISCO, Calif. , March 14, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication of abstracts at the 2023 Annual Meeting of the American Association for Cancer Research (AACR). IDEAYA will present data for its potential first-in-class synthetic... Read More

Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into 2026 Planning regulatory update on potential registration-enabling clinical trial for darovasertib / crizotinib combination in MUM following scheduled FDA meeting in Q1 2023 Targeting mid-year 2023 darovasertib / crizotinib clinical efficacy update with approximately... Read More

SOUTH SAN FRANCISCO, Calif. , March 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in March 2023 . Oppenheimer 33 rd Annual Healthcare Conference Tuesday, March 14 th , 2023 at 1:20 PM ET Fireside chat with Michael White ,... Read More

SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in Citi's 2023 Virtual Oncology Leadership Summit. Citi's 2023 Virtual Oncology Leadership Summit Tuesday, February 21, 2023 at 9:00 AM ET ( 6:00 AM PT ) Fireside... Read More

SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the 2023 Guggenheim Oncology Conference. 2023 Guggenheim Oncology Conference Thursday, February 9, 2023 at 7:45 AM PT ( 10:45 AM ET ) Fireside chat with Yujiro S.... Read More

Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of enucleation or radiation therapy Clinical protocol includes neoadjuvant treatment with Darovasertib to maximum benefit up to 6 months, primary treatment, then up to 6 months of follow-up adjuvant therapy Neoadjuvant endpoints include eye preservation, reducing radiation and vision... Read More

Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer Starting dose of IDE161 in the Phase 1 dose escalation is one-half of the projected human efficacious dose, based on preclinical studies IDE161 monotherapy clinical focus includes ER+ / Her2- breast cancer with HRD, representing approximately 10% to 14% of... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 41st Annual J.P. Morgan Healthcare Conference. J.P. Morgan 41st Annual Healthcare Conference Tuesday, January 10, 2023 at 4:30 pm PT ( 7:30 pm ET )... Read More

Dr. Karlene Cimprich , Ph.D. ( Stanford University ), is a leading scientist in replication stress mechanisms and regulation of DNA Damage Repair pathways Dr. Kornelia Polyak , M.D., Ph.D. (DFCI, Harvard University ) is a renowned physician-scientist focused on breast cancer clinical management and tumor biology SOUTH SAN FRANCISCO, Calif. , Dec. 19, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic... Read More

IDE161 is being developed as a potential first-in-class PARG inhibitor for patients having tumors with HRD, with an initial focus in BRCA1/2-mutant Breast and Ovarian Cancer Proposed clinical development plan for IDE161 to be highlighted in Investor R&D Day webcast being hosted by IDEAYA today, December 12, 2022 , at 8:00 am ET SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:... Read More

Fast Track designation granted by U.S. FDA for evaluation of darovasertib in combination with crizotinib in adult patients being treated for metastatic uveal melanoma (MUM) Enables darovasertib / crizotinib development program to access expedited regulatory review processes, including potential eligibility for accelerated approval / priority review SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2022 /PRNewswire/ -- IDEAYA... Read More

SOUTH SAN FRANCISCO, Calif. , Nov. 29, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics and participating key opinion leaders for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 12, 2022 at 8:00 am - 9:30 am ET.... Read More

Former Senior Vice President and Head of Early Oncology Development and Clinical Research at Pfizer will lead IDEAYA's clinical development efforts as Chief Medical Officer Over twenty-five years of experience in clinical development and translational research, including at leading pharmaceutical companies and major research institutions SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2022 /PRNewswire/ -- I DEAYA Biosciences, Inc.... Read More